189 filings
Page 2 of 10
8-K
9acx0q1dk6fjd
8 May 23
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
7:45am
8-K
4l3 10yctfak
1 May 23
MaRKER Announces LeADERSHIP TRANSITIONÂ & ProVIdes UPDATE ON OPERATIONAL STRATEGY
7:36am
8-K
qtak3is6nyo8xz0
22 Mar 23
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
8:18am
8-K
l2x 9bfbny
16 Mar 23
Departure of Directors or Certain Officers
4:05pm
8-K
u7zq3r53atlc96bkj6s
26 Jan 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
8-K
jjujkcwv 76v
13 Dec 22
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
7:30am
8-K
rvxh4i5gald
22 Nov 22
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
7:15am
8-K
97j7q f23
10 Nov 22
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
4:16pm
8-K
081o rthx7plzivgdr
20 Oct 22
Termination of a Material Definitive Agreement
4:31pm
8-K
ol05ny
27 Sep 22
Departure of Directors or Certain Officers
8:45am
8-K
ax4k0g0aewe0ppwwh9o
13 Sep 22
Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker’s Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML
9:16am
8-K
630xqxsusr0pzmgf63y
19 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
3h5 sbfc40ibav
11 Aug 22
Marker Therapeutics Reports Q2 2022 Operating and Financial Results
4:41pm
8-K
63nxe5g7
4 Aug 22
Company expects to initiate Phase 1 trial of MT-601 in r/r NHL in 2023
4:50pm
8-K
k731i3c0e1bg8 ahcd
27 May 22
Amendments to Articles of Incorporation or Bylaws
4:06pm
8-K
z2w0ymbltbwhf pybl
13 May 22
Marker Therapeutics Reports Q1 2022 Operating and Financial Results
7:11am
8-K
zb1iyiv83x6
26 Apr 22
Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf
7:24am
8-K
fugvn
6 Apr 22
Departure of Directors or Certain Officers
4:08pm
8-K
ajkcnrht108f 2oi5l
17 Mar 22
Marker Therapeutics Reports Fiscal Year 2021 Operating and Financial Results
6:21pm
8-K
0cppa phjyr
18 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm